 | • レポートコード：QFJ1-4615 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、127ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、眼科疾患治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口薬、注射薬、外用薬）、用途別市場規模（若年性黄斑変性症（シュタルガルト病）、レーバー先天性黒内障（LCA）、レーバー遺伝性視神経症（LHON）（レーバー視神経萎縮症）、アッシャー症候群、網膜色素変性症（網膜炎））、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・眼科疾患治療薬の市場動向 ・企業の競争状況、市場シェア ・眼科疾患治療薬の種類別市場規模と予測2016-2027（経口薬、注射薬、外用薬） ・眼科疾患治療薬の用途別市場規模と予測2016-2027（若年性黄斑変性症（シュタルガルト病）、レーバー先天性黒内障（LCA）、レーバー遺伝性視神経症（LHON）（レーバー視神経萎縮症）、アッシャー症候群、網膜色素変性症（網膜炎）） ・眼科疾患治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・眼科疾患治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・眼科疾患治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・眼科疾患治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・眼科疾患治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Sanofi、Bayer、Bausch + Lomb、Novartis、Usher Syndrome、Takeda Pharmaceutical、Roche、Pfizer、Allergan、Gilead Sciences、Kubota Pharmaceutical、Alkeus Pharmaceuticals、Astellas Pharma、Ferrer Corporate、Amgen Inc、Editas Medicine Inc、ProQR Therapeutics NV、ReNeuron、Amarantus BioScience、Ocugen、ReGenX Biosciences、Sucampo Pharmaceuticals、Orphagen Pharmaceuticals、Okuvision、Second Sight Medical、Acucela、Stealth BioTherapeutics、Sun Pharma Advanced Research Company、AmpliPhi Biosciences、Applied Genetic Technologies、Asklepios BioPharmaceutical、Biovista、Spark Therapeutics、Caladrius Biosciences、Dompe Farmaceutici、Dormant Projects、Grupo Ferrer Internacional、ID Pharma、InFlectis BioScience、Ionis Pharmaceuticals、Ixchel Pharma、Khondrion、Mimetogen Pharmaceuticals、Mitotech、M's Science、Nanovector、SanBio） ・結論 |
Macular degeneration is a group of eye disease commonly found among children and adults. There are various types of macular degeneration affecting the teens such as Cone-Rod Dystrophy, Best disease, Stargardt disease, Corneal Dystrophy, and Fuch’s Dystrophy.Retinitis pigmentosa is generally inherited from a person’s parents. Mutations in one of more than 50 genes is involved.
Market Analysis and Insights: Global Ophthalmology Disorders Drug Market
The global Ophthalmology Disorders Drug market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Ophthalmology Disorders Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Ophthalmology Disorders Drug market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Ophthalmology Disorders Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Ophthalmology Disorders Drug market.
Global Ophthalmology Disorders Drug Scope and Market Size
Ophthalmology Disorders Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Ophthalmology Disorders Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Oral
Injection
External Use
Segment by Application
Juvenile Macular Degeneration (Stargardt Disease)
Leber Congenital Amaurosis (LCA)
Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy)
Usher Syndrome
Retinitis Pigmentosa (Retinitis)
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Sanofi
Bayer
Bausch + Lomb
Novartis
Usher Syndrome
Takeda Pharmaceutical
Roche
Pfizer
Allergan
Gilead Sciences
Kubota Pharmaceutical
Alkeus Pharmaceuticals
Astellas Pharma
Ferrer Corporate
Amgen Inc
Editas Medicine Inc
ProQR Therapeutics NV
ReNeuron
Amarantus BioScience
Ocugen
ReGenX Biosciences
Sucampo Pharmaceuticals
Orphagen Pharmaceuticals
Okuvision
Second Sight Medical
Acucela
Stealth BioTherapeutics
Sun Pharma Advanced Research Company
AmpliPhi Biosciences
Applied Genetic Technologies
Asklepios BioPharmaceutical
Biovista
Spark Therapeutics
Caladrius Biosciences
Dompe Farmaceutici
Dormant Projects
Grupo Ferrer Internacional
ID Pharma
InFlectis BioScience
Ionis Pharmaceuticals
Ixchel Pharma
Khondrion
Mimetogen Pharmaceuticals
Mitotech
M’s Science
Nanovector
SanBio
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Ophthalmology Disorders Drug Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Oral
1.2.3 Injection
1.2.4 External Use
1.3 Market by Application
1.3.1 Global Ophthalmology Disorders Drug Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Juvenile Macular Degeneration (Stargardt Disease)
1.3.3 Leber Congenital Amaurosis (LCA)
1.3.4 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy)
1.3.5 Usher Syndrome
1.3.6 Retinitis Pigmentosa (Retinitis)
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Ophthalmology Disorders Drug Market Perspective (2016-2027)
2.2 Ophthalmology Disorders Drug Growth Trends by Regions
2.2.1 Ophthalmology Disorders Drug Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Ophthalmology Disorders Drug Historic Market Share by Regions (2016-2021)
2.2.3 Ophthalmology Disorders Drug Forecasted Market Size by Regions (2022-2027)
2.3 Ophthalmology Disorders Drug Industry Dynamic
2.3.1 Ophthalmology Disorders Drug Market Trends
2.3.2 Ophthalmology Disorders Drug Market Drivers
2.3.3 Ophthalmology Disorders Drug Market Challenges
2.3.4 Ophthalmology Disorders Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Ophthalmology Disorders Drug Players by Revenue
3.1.1 Global Top Ophthalmology Disorders Drug Players by Revenue (2016-2021)
3.1.2 Global Ophthalmology Disorders Drug Revenue Market Share by Players (2016-2021)
3.2 Global Ophthalmology Disorders Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Ophthalmology Disorders Drug Revenue
3.4 Global Ophthalmology Disorders Drug Market Concentration Ratio
3.4.1 Global Ophthalmology Disorders Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Ophthalmology Disorders Drug Revenue in 2020
3.5 Ophthalmology Disorders Drug Key Players Head office and Area Served
3.6 Key Players Ophthalmology Disorders Drug Product Solution and Service
3.7 Date of Enter into Ophthalmology Disorders Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Ophthalmology Disorders Drug Breakdown Data by Type
4.1 Global Ophthalmology Disorders Drug Historic Market Size by Type (2016-2021)
4.2 Global Ophthalmology Disorders Drug Forecasted Market Size by Type (2022-2027)
5 Ophthalmology Disorders Drug Breakdown Data by Application
5.1 Global Ophthalmology Disorders Drug Historic Market Size by Application (2016-2021)
5.2 Global Ophthalmology Disorders Drug Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Ophthalmology Disorders Drug Market Size (2016-2027)
6.2 North America Ophthalmology Disorders Drug Market Size by Type
6.2.1 North America Ophthalmology Disorders Drug Market Size by Type (2016-2021)
6.2.2 North America Ophthalmology Disorders Drug Market Size by Type (2022-2027)
6.2.3 North America Ophthalmology Disorders Drug Market Size by Type (2016-2027)
6.3 North America Ophthalmology Disorders Drug Market Size by Application
6.3.1 North America Ophthalmology Disorders Drug Market Size by Application (2016-2021)
6.3.2 North America Ophthalmology Disorders Drug Market Size by Application (2022-2027)
6.3.3 North America Ophthalmology Disorders Drug Market Size by Application (2016-2027)
6.4 North America Ophthalmology Disorders Drug Market Size by Country
6.4.1 North America Ophthalmology Disorders Drug Market Size by Country (2016-2021)
6.4.2 North America Ophthalmology Disorders Drug Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Ophthalmology Disorders Drug Market Size (2016-2027)
7.2 Europe Ophthalmology Disorders Drug Market Size by Type
7.2.1 Europe Ophthalmology Disorders Drug Market Size by Type (2016-2021)
7.2.2 Europe Ophthalmology Disorders Drug Market Size by Type (2022-2027)
7.2.3 Europe Ophthalmology Disorders Drug Market Size by Type (2016-2027)
7.3 Europe Ophthalmology Disorders Drug Market Size by Application
7.3.1 Europe Ophthalmology Disorders Drug Market Size by Application (2016-2021)
7.3.2 Europe Ophthalmology Disorders Drug Market Size by Application (2022-2027)
7.3.3 Europe Ophthalmology Disorders Drug Market Size by Application (2016-2027)
7.4 Europe Ophthalmology Disorders Drug Market Size by Country
7.4.1 Europe Ophthalmology Disorders Drug Market Size by Country (2016-2021)
7.4.2 Europe Ophthalmology Disorders Drug Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Ophthalmology Disorders Drug Market Size (2016-2027)
8.2 Asia-Pacific Ophthalmology Disorders Drug Market Size by Type
8.2.1 Asia-Pacific Ophthalmology Disorders Drug Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Ophthalmology Disorders Drug Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Ophthalmology Disorders Drug Market Size by Type (2016-2027)
8.3 Asia-Pacific Ophthalmology Disorders Drug Market Size by Application
8.3.1 Asia-Pacific Ophthalmology Disorders Drug Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Ophthalmology Disorders Drug Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Ophthalmology Disorders Drug Market Size by Application (2016-2027)
8.4 Asia-Pacific Ophthalmology Disorders Drug Market Size by Region
8.4.1 Asia-Pacific Ophthalmology Disorders Drug Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Ophthalmology Disorders Drug Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Ophthalmology Disorders Drug Market Size (2016-2027)
9.2 Latin America Ophthalmology Disorders Drug Market Size by Type
9.2.1 Latin America Ophthalmology Disorders Drug Market Size by Type (2016-2021)
9.2.2 Latin America Ophthalmology Disorders Drug Market Size by Type (2022-2027)
9.2.3 Latin America Ophthalmology Disorders Drug Market Size by Type (2016-2027)
9.3 Latin America Ophthalmology Disorders Drug Market Size by Application
9.3.1 Latin America Ophthalmology Disorders Drug Market Size by Application (2016-2021)
9.3.2 Latin America Ophthalmology Disorders Drug Market Size by Application (2022-2027)
9.3.3 Latin America Ophthalmology Disorders Drug Market Size by Application (2016-2027)
9.4 Latin America Ophthalmology Disorders Drug Market Size by Country
9.4.1 Latin America Ophthalmology Disorders Drug Market Size by Country (2016-2021)
9.4.2 Latin America Ophthalmology Disorders Drug Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Ophthalmology Disorders Drug Market Size (2016-2027)
10.2 Middle East & Africa Ophthalmology Disorders Drug Market Size by Type
10.2.1 Middle East & Africa Ophthalmology Disorders Drug Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Ophthalmology Disorders Drug Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Ophthalmology Disorders Drug Market Size by Type (2016-2027)
10.3 Middle East & Africa Ophthalmology Disorders Drug Market Size by Application
10.3.1 Middle East & Africa Ophthalmology Disorders Drug Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Ophthalmology Disorders Drug Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Ophthalmology Disorders Drug Market Size by Application (2016-2027)
10.4 Middle East & Africa Ophthalmology Disorders Drug Market Size by Country
10.4.1 Middle East & Africa Ophthalmology Disorders Drug Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Ophthalmology Disorders Drug Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Ophthalmology Disorders Drug Introduction
11.1.4 Sanofi Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.1.5 Sanofi Recent Development
11.2 Bayer
11.2.1 Bayer Company Details
11.2.2 Bayer Business Overview
11.2.3 Bayer Ophthalmology Disorders Drug Introduction
11.2.4 Bayer Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.2.5 Bayer Recent Development
11.3 Bausch + Lomb
11.3.1 Bausch + Lomb Company Details
11.3.2 Bausch + Lomb Business Overview
11.3.3 Bausch + Lomb Ophthalmology Disorders Drug Introduction
11.3.4 Bausch + Lomb Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.3.5 Bausch + Lomb Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Ophthalmology Disorders Drug Introduction
11.4.4 Novartis Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.4.5 Novartis Recent Development
11.5 Usher Syndrome
11.5.1 Usher Syndrome Company Details
11.5.2 Usher Syndrome Business Overview
11.5.3 Usher Syndrome Ophthalmology Disorders Drug Introduction
11.5.4 Usher Syndrome Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.5.5 Usher Syndrome Recent Development
11.6 Takeda Pharmaceutical
11.6.1 Takeda Pharmaceutical Company Details
11.6.2 Takeda Pharmaceutical Business Overview
11.6.3 Takeda Pharmaceutical Ophthalmology Disorders Drug Introduction
11.6.4 Takeda Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.6.5 Takeda Pharmaceutical Recent Development
11.7 Roche
11.7.1 Roche Company Details
11.7.2 Roche Business Overview
11.7.3 Roche Ophthalmology Disorders Drug Introduction
11.7.4 Roche Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.7.5 Roche Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Details
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Ophthalmology Disorders Drug Introduction
11.8.4 Pfizer Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.8.5 Pfizer Recent Development
11.9 Allergan
11.9.1 Allergan Company Details
11.9.2 Allergan Business Overview
11.9.3 Allergan Ophthalmology Disorders Drug Introduction
11.9.4 Allergan Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.9.5 Allergan Recent Development
11.10 Gilead Sciences
11.10.1 Gilead Sciences Company Details
11.10.2 Gilead Sciences Business Overview
11.10.3 Gilead Sciences Ophthalmology Disorders Drug Introduction
11.10.4 Gilead Sciences Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.10.5 Gilead Sciences Recent Development
11.11 Kubota Pharmaceutical
11.11.1 Kubota Pharmaceutical Company Details
11.11.2 Kubota Pharmaceutical Business Overview
11.11.3 Kubota Pharmaceutical Ophthalmology Disorders Drug Introduction
11.11.4 Kubota Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.11.5 Kubota Pharmaceutical Recent Development
11.12 Alkeus Pharmaceuticals
11.12.1 Alkeus Pharmaceuticals Company Details
11.12.2 Alkeus Pharmaceuticals Business Overview
11.12.3 Alkeus Pharmaceuticals Ophthalmology Disorders Drug Introduction
11.12.4 Alkeus Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.12.5 Alkeus Pharmaceuticals Recent Development
11.13 Astellas Pharma
11.13.1 Astellas Pharma Company Details
11.13.2 Astellas Pharma Business Overview
11.13.3 Astellas Pharma Ophthalmology Disorders Drug Introduction
11.13.4 Astellas Pharma Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.13.5 Astellas Pharma Recent Development
11.14 Ferrer Corporate
11.14.1 Ferrer Corporate Company Details
11.14.2 Ferrer Corporate Business Overview
11.14.3 Ferrer Corporate Ophthalmology Disorders Drug Introduction
11.14.4 Ferrer Corporate Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.14.5 Ferrer Corporate Recent Development
11.15 Amgen Inc
11.15.1 Amgen Inc Company Details
11.15.2 Amgen Inc Business Overview
11.15.3 Amgen Inc Ophthalmology Disorders Drug Introduction
11.15.4 Amgen Inc Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.15.5 Amgen Inc Recent Development
11.16 Editas Medicine Inc
11.16.1 Editas Medicine Inc Company Details
11.16.2 Editas Medicine Inc Business Overview
11.16.3 Editas Medicine Inc Ophthalmology Disorders Drug Introduction
11.16.4 Editas Medicine Inc Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.16.5 Editas Medicine Inc Recent Development
11.17 ProQR Therapeutics NV
11.17.1 ProQR Therapeutics NV Company Details
11.17.2 ProQR Therapeutics NV Business Overview
11.17.3 ProQR Therapeutics NV Ophthalmology Disorders Drug Introduction
11.17.4 ProQR Therapeutics NV Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.17.5 ProQR Therapeutics NV Recent Development
11.18 ReNeuron
11.18.1 ReNeuron Company Details
11.18.2 ReNeuron Business Overview
11.18.3 ReNeuron Ophthalmology Disorders Drug Introduction
11.18.4 ReNeuron Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.18.5 ReNeuron Recent Development
11.18 Amarantus BioScience
11.25.1 Amarantus BioScience Company Details
11.25.2 Amarantus BioScience Business Overview
11.25.3 Amarantus BioScience Ophthalmology Disorders Drug Introduction
11.25.4 Amarantus BioScience Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.25.5 Amarantus BioScience Recent Development
11.20 Ocugen
11.20.1 Ocugen Company Details
11.20.2 Ocugen Business Overview
11.20.3 Ocugen Ophthalmology Disorders Drug Introduction
11.20.4 Ocugen Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.20.5 Ocugen Recent Development
11.21 ReGenX Biosciences
11.21.1 ReGenX Biosciences Company Details
11.21.2 ReGenX Biosciences Business Overview
11.21.3 ReGenX Biosciences Ophthalmology Disorders Drug Introduction
11.21.4 ReGenX Biosciences Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.21.5 ReGenX Biosciences Recent Development
11.22 Sucampo Pharmaceuticals
11.22.1 Sucampo Pharmaceuticals Company Details
11.22.2 Sucampo Pharmaceuticals Business Overview
11.22.3 Sucampo Pharmaceuticals Ophthalmology Disorders Drug Introduction
11.22.4 Sucampo Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.22.5 Sucampo Pharmaceuticals Recent Development
11.23 Orphagen Pharmaceuticals
11.23.1 Orphagen Pharmaceuticals Company Details
11.23.2 Orphagen Pharmaceuticals Business Overview
11.23.3 Orphagen Pharmaceuticals Ophthalmology Disorders Drug Introduction
11.23.4 Orphagen Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.23.5 Orphagen Pharmaceuticals Recent Development
11.24 Okuvision
11.24.1 Okuvision Company Details
11.24.2 Okuvision Business Overview
11.24.3 Okuvision Ophthalmology Disorders Drug Introduction
11.24.4 Okuvision Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.24.5 Okuvision Recent Development
11.25 Second Sight Medical
11.25.1 Second Sight Medical Company Details
11.25.2 Second Sight Medical Business Overview
11.25.3 Second Sight Medical Ophthalmology Disorders Drug Introduction
11.25.4 Second Sight Medical Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.25.5 Second Sight Medical Recent Development
11.26 Acucela
11.26.1 Acucela Company Details
11.26.2 Acucela Business Overview
11.26.3 Acucela Ophthalmology Disorders Drug Introduction
11.26.4 Acucela Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.26.5 Acucela Recent Development
11.27 Stealth BioTherapeutics
11.27.1 Stealth BioTherapeutics Company Details
11.27.2 Stealth BioTherapeutics Business Overview
11.27.3 Stealth BioTherapeutics Ophthalmology Disorders Drug Introduction
11.27.4 Stealth BioTherapeutics Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.27.5 Stealth BioTherapeutics Recent Development
11.28 Sun Pharma Advanced Research Company
11.28.1 Sun Pharma Advanced Research Company Company Details
11.28.2 Sun Pharma Advanced Research Company Business Overview
11.28.3 Sun Pharma Advanced Research Company Ophthalmology Disorders Drug Introduction
11.28.4 Sun Pharma Advanced Research Company Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.28.5 Sun Pharma Advanced Research Company Recent Development
11.29 AmpliPhi Biosciences
11.29.1 AmpliPhi Biosciences Company Details
11.29.2 AmpliPhi Biosciences Business Overview
11.29.3 AmpliPhi Biosciences Ophthalmology Disorders Drug Introduction
11.29.4 AmpliPhi Biosciences Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.29.5 AmpliPhi Biosciences Recent Development
11.30 Applied Genetic Technologies
11.30.1 Applied Genetic Technologies Company Details
11.30.2 Applied Genetic Technologies Business Overview
11.30.3 Applied Genetic Technologies Ophthalmology Disorders Drug Introduction
11.30.4 Applied Genetic Technologies Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.30.5 Applied Genetic Technologies Recent Development
11.31 Asklepios BioPharmaceutical
11.31.1 Asklepios BioPharmaceutical Company Details
11.31.2 Asklepios BioPharmaceutical Business Overview
11.31.3 Asklepios BioPharmaceutical Ophthalmology Disorders Drug Introduction
11.31.4 Asklepios BioPharmaceutical Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.31.5 Asklepios BioPharmaceutical Recent Development
11.32 Biovista
11.32.1 Biovista Company Details
11.32.2 Biovista Business Overview
11.32.3 Biovista Ophthalmology Disorders Drug Introduction
11.32.4 Biovista Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.32.5 Biovista Recent Development
11.33 Spark Therapeutics
11.33.1 Spark Therapeutics Company Details
11.33.2 Spark Therapeutics Business Overview
11.33.3 Spark Therapeutics Ophthalmology Disorders Drug Introduction
11.33.4 Spark Therapeutics Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.33.5 Spark Therapeutics Recent Development
11.34 Caladrius Biosciences
11.34.1 Caladrius Biosciences Company Details
11.34.2 Caladrius Biosciences Business Overview
11.34.3 Caladrius Biosciences Ophthalmology Disorders Drug Introduction
11.34.4 Caladrius Biosciences Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.34.5 Caladrius Biosciences Recent Development
11.35 Dompe Farmaceutici
11.35.1 Dompe Farmaceutici Company Details
11.35.2 Dompe Farmaceutici Business Overview
11.35.3 Dompe Farmaceutici Ophthalmology Disorders Drug Introduction
11.35.4 Dompe Farmaceutici Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.35.5 Dompe Farmaceutici Recent Development
11.36 Dormant Projects
11.36.1 Dormant Projects Company Details
11.36.2 Dormant Projects Business Overview
11.36.3 Dormant Projects Ophthalmology Disorders Drug Introduction
11.36.4 Dormant Projects Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.36.5 Dormant Projects Recent Development
11.37 Grupo Ferrer Internacional
11.37.1 Grupo Ferrer Internacional Company Details
11.37.2 Grupo Ferrer Internacional Business Overview
11.37.3 Grupo Ferrer Internacional Ophthalmology Disorders Drug Introduction
11.37.4 Grupo Ferrer Internacional Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.37.5 Grupo Ferrer Internacional Recent Development
11.38 ID Pharma
11.38.1 ID Pharma Company Details
11.38.2 ID Pharma Business Overview
11.38.3 ID Pharma Ophthalmology Disorders Drug Introduction
11.38.4 ID Pharma Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.38.5 ID Pharma Recent Development
11.39 InFlectis BioScience
11.39.1 InFlectis BioScience Company Details
11.39.2 InFlectis BioScience Business Overview
11.39.3 InFlectis BioScience Ophthalmology Disorders Drug Introduction
11.39.4 InFlectis BioScience Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.39.5 InFlectis BioScience Recent Development
11.40 Ionis Pharmaceuticals
11.40.1 Ionis Pharmaceuticals Company Details
11.40.2 Ionis Pharmaceuticals Business Overview
11.40.3 Ionis Pharmaceuticals Ophthalmology Disorders Drug Introduction
11.40.4 Ionis Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2016-2021)
11.40.5 Ionis Pharmaceuticals Recent Development
11.41 Ixchel Pharma
11.42 Khondrion
11.43 Mimetogen Pharmaceuticals
11.44 Mitotech
11.45 M’s Science
11.46 Nanovector
11.47 SanBio
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Ophthalmology Disorders Drug Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Oral
Table 3. Key Players of Injection
Table 4. Key Players of External Use
Table 5. Global Ophthalmology Disorders Drug Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Ophthalmology Disorders Drug Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Ophthalmology Disorders Drug Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Ophthalmology Disorders Drug Market Share by Regions (2016-2021)
Table 9. Global Ophthalmology Disorders Drug Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Ophthalmology Disorders Drug Market Share by Regions (2022-2027)
Table 11. Ophthalmology Disorders Drug Market Trends
Table 12. Ophthalmology Disorders Drug Market Drivers
Table 13. Ophthalmology Disorders Drug Market Challenges
Table 14. Ophthalmology Disorders Drug Market Restraints
Table 15. Global Ophthalmology Disorders Drug Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Ophthalmology Disorders Drug Market Share by Players (2016-2021)
Table 17. Global Top Ophthalmology Disorders Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ophthalmology Disorders Drug as of 2020)
Table 18. Ranking of Global Top Ophthalmology Disorders Drug Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Ophthalmology Disorders Drug Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Ophthalmology Disorders Drug Product Solution and Service
Table 22. Date of Enter into Ophthalmology Disorders Drug Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Ophthalmology Disorders Drug Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Ophthalmology Disorders Drug Revenue Market Share by Type (2016-2021)
Table 26. Global Ophthalmology Disorders Drug Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Ophthalmology Disorders Drug Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Ophthalmology Disorders Drug Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Ophthalmology Disorders Drug Revenue Market Share by Application (2016-2021)
Table 30. Global Ophthalmology Disorders Drug Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Ophthalmology Disorders Drug Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Ophthalmology Disorders Drug Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Ophthalmology Disorders Drug Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Ophthalmology Disorders Drug Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Ophthalmology Disorders Drug Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Ophthalmology Disorders Drug Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Ophthalmology Disorders Drug Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Ophthalmology Disorders Drug Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Ophthalmology Disorders Drug Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Ophthalmology Disorders Drug Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Ophthalmology Disorders Drug Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Ophthalmology Disorders Drug Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Ophthalmology Disorders Drug Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Ophthalmology Disorders Drug Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Ophthalmology Disorders Drug Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Ophthalmology Disorders Drug Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Ophthalmology Disorders Drug Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Ophthalmology Disorders Drug Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Ophthalmology Disorders Drug Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Ophthalmology Disorders Drug Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Ophthalmology Disorders Drug Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Ophthalmology Disorders Drug Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Ophthalmology Disorders Drug Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Ophthalmology Disorders Drug Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Ophthalmology Disorders Drug Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Ophthalmology Disorders Drug Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Ophthalmology Disorders Drug Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Ophthalmology Disorders Drug Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Ophthalmology Disorders Drug Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Ophthalmology Disorders Drug Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Ophthalmology Disorders Drug Market Size by Country (2022-2027) & (US$ Million)
Table 62. Sanofi Company Details
Table 63. Sanofi Business Overview
Table 64. Sanofi Ophthalmology Disorders Drug Product
Table 65. Sanofi Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 66. Sanofi Recent Development
Table 67. Bayer Company Details
Table 68. Bayer Business Overview
Table 69. Bayer Ophthalmology Disorders Drug Product
Table 70. Bayer Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 71. Bayer Recent Development
Table 72. Bausch + Lomb Company Details
Table 73. Bausch + Lomb Business Overview
Table 74. Bausch + Lomb Ophthalmology Disorders Drug Product
Table 75. Bausch + Lomb Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 76. Bausch + Lomb Recent Development
Table 77. Novartis Company Details
Table 78. Novartis Business Overview
Table 79. Novartis Ophthalmology Disorders Drug Product
Table 80. Novartis Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 81. Novartis Recent Development
Table 82. Usher Syndrome Company Details
Table 83. Usher Syndrome Business Overview
Table 84. Usher Syndrome Ophthalmology Disorders Drug Product
Table 85. Usher Syndrome Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 86. Usher Syndrome Recent Development
Table 87. Takeda Pharmaceutical Company Details
Table 88. Takeda Pharmaceutical Business Overview
Table 89. Takeda Pharmaceutical Ophthalmology Disorders Drug Product
Table 90. Takeda Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 91. Takeda Pharmaceutical Recent Development
Table 92. Roche Company Details
Table 93. Roche Business Overview
Table 94. Roche Ophthalmology Disorders Drug Product
Table 95. Roche Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 96. Roche Recent Development
Table 97. Pfizer Company Details
Table 98. Pfizer Business Overview
Table 99. Pfizer Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 100. Pfizer Recent Development
Table 101. Allergan Company Details
Table 102. Allergan Business Overview
Table 103. Allergan Ophthalmology Disorders Drug Product
Table 104. Allergan Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 105. Allergan Recent Development
Table 106. Gilead Sciences Company Details
Table 107. Gilead Sciences Business Overview
Table 108. Gilead Sciences Ophthalmology Disorders Drug Product
Table 109. Gilead Sciences Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 110. Gilead Sciences Recent Development
Table 111. Kubota Pharmaceutical Company Details
Table 112. Kubota Pharmaceutical Business Overview
Table 113. Kubota Pharmaceutical Ophthalmology Disorders Drug Product
Table 114. Kubota Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 115. Kubota Pharmaceutical Recent Development
Table 116. Alkeus Pharmaceuticals Company Details
Table 117. Alkeus Pharmaceuticals Business Overview
Table 118. Alkeus Pharmaceuticals Ophthalmology Disorders Drug Product
Table 119. Alkeus Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 120. Alkeus Pharmaceuticals Recent Development
Table 121. Astellas Pharma Company Details
Table 122. Astellas Pharma Business Overview
Table 123. Astellas Pharma Ophthalmology Disorders Drug Product
Table 124. Astellas Pharma Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 125. Astellas Pharma Recent Development
Table 126. Ferrer Corporate Company Details
Table 127. Ferrer Corporate Business Overview
Table 128. Ferrer Corporate Ophthalmology Disorders Drug Product
Table 129. Ferrer Corporate Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 130. Ferrer Corporate Recent Development
Table 131. Amgen Inc Company Details
Table 132. Amgen Inc Business Overview
Table 133. Amgen Inc Ophthalmology Disorders Drug Product
Table 134. Amgen Inc Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 135. Amgen Inc Recent Development
Table 136. Editas Medicine Inc Company Details
Table 137. Editas Medicine Inc Business Overview
Table 138. Editas Medicine Inc Ophthalmology Disorders Drug Product
Table 139. Editas Medicine Inc Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 140. Editas Medicine Inc Recent Development
Table 141. ProQR Therapeutics NV Company Details
Table 142. ProQR Therapeutics NV Business Overview
Table 143. ProQR Therapeutics NV Ophthalmology Disorders Drug Product
Table 144. ProQR Therapeutics NV Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 145. ProQR Therapeutics NV Recent Development
Table 146. ReNeuron Company Details
Table 147. ReNeuron Business Overview
Table 148. ReNeuron Ophthalmology Disorders Drug Product
Table 149. ReNeuron Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 150. ReNeuron Recent Development
Table 151. Amarantus BioScience Company Details
Table 152. Amarantus BioScience Business Overview
Table 153. Amarantus BioScience Ophthalmology Disorders Drug Product
Table 154. Amarantus BioScience Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 155. Amarantus BioScience Recent Development
Table 156. Ocugen Company Details
Table 157. Ocugen Business Overview
Table 158. Ocugen Ophthalmology Disorders Drug Product
Table 159. Ocugen Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 160. Ocugen Recent Development
Table 161. ReGenX Biosciences Company Details
Table 162. ReGenX Biosciences Business Overview
Table 163. ReGenX Biosciences Ophthalmology Disorders Drug Product
Table 164. ReGenX Biosciences Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 165. ReGenX Biosciences Recent Development
Table 166. Sucampo Pharmaceuticals Company Details
Table 167. Sucampo Pharmaceuticals Business Overview
Table 168. Sucampo Pharmaceuticals Ophthalmology Disorders Drug Product
Table 169. Sucampo Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 170. Sucampo Pharmaceuticals Recent Development
Table 171. Orphagen Pharmaceuticals Company Details
Table 172. Orphagen Pharmaceuticals Business Overview
Table 173. Orphagen Pharmaceuticals Ophthalmology Disorders Drug Product
Table 174. Orphagen Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 175. Orphagen Pharmaceuticals Recent Development
Table 176. Okuvision Company Details
Table 177. Okuvision Business Overview
Table 178. Okuvision Ophthalmology Disorders DrugProduct
Table 179. Okuvision Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 180. Okuvision Recent Development
Table 181. Second Sight Medical Company Details
Table 182. Second Sight Medical Business Overview
Table 183. Second Sight Medical Ophthalmology Disorders Drug Product
Table 184. Second Sight Medical Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 185. Second Sight Medical Recent Development
Table 186. Acucela Company Details
Table 187. Acucela Business Overview
Table 188. Acucela Ophthalmology Disorders Drug Product
Table 189. Acucela Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 190. Acucela Recent Development
Table 191. Stealth BioTherapeutics Company Details
Table 192. Stealth BioTherapeutics Business Overview
Table 193. Stealth BioTherapeutics Ophthalmology Disorders Drug Product
Table 194. Stealth BioTherapeutics Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 195. Stealth BioTherapeutics Recent Development
Table 196. Sun Pharma Advanced Research Company Company Details
Table 197. Sun Pharma Advanced Research Company Business Overview
Table 198. Sun Pharma Advanced Research Company Ophthalmology Disorders Drug Product
Table 199. Sun Pharma Advanced Research Company Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 200. Sun Pharma Advanced Research Company Recent Development
Table 201. AmpliPhi Biosciences Company Details
Table 202. AmpliPhi Biosciences Business Overview
Table 203. AmpliPhi Biosciences Ophthalmology Disorders Drug Product
Table 204. AmpliPhi Biosciences Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 205. AmpliPhi Biosciences Recent Development
Table 206. Applied Genetic Technologies Company Details
Table 207. Applied Genetic Technologies Business Overview
Table 208. Applied Genetic Technologies Ophthalmology Disorders Drug Product
Table 209. Applied Genetic Technologies Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 210. Applied Genetic Technologies Recent Development
Table 211. Asklepios BioPharmaceutical Company Details
Table 212. Asklepios BioPharmaceutical Business Overview
Table 213. Asklepios BioPharmaceutical Ophthalmology Disorders Drug Product
Table 214. Asklepios BioPharmaceutical Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 215. Asklepios BioPharmaceutical Recent Development
Table 216. Biovista Company Details
Table 217. Biovista Business Overview
Table 218. Biovista Ophthalmology Disorders Drug Product
Table 219. Biovista Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 220. Biovista Recent Development
Table 221. Spark Therapeutics Company Details
Table 222. Spark Therapeutics Business Overview
Table 223. Spark Therapeutics Ophthalmology Disorders Drug Product
Table 224. Spark Therapeutics Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 225. Spark Therapeutics Recent Development
Table 226. Caladrius Biosciences Company Details
Table 227. Caladrius Biosciences Business Overview
Table 228. Caladrius Biosciences Ophthalmology Disorders Drug Product
Table 229. Caladrius Biosciences Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 230. Caladrius Biosciences Recent Development
Table 231. Dompe Farmaceutici Company Details
Table 232. Dompe Farmaceutici Business Overview
Table 233. Dompe Farmaceutici Ophthalmology Disorders Drug Product
Table 234. Dompe Farmaceutici Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 235. Dompe Farmaceutici Recent Development
Table 236. Dormant Projects Company Details
Table 237. Dormant Projects Business Overview
Table 238. Dormant Projects Ophthalmology Disorders Drug Product
Table 239. Dormant Projects Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 240. Dormant Projects Recent Development
Table 241. Grupo Ferrer Internacional Company Details
Table 242. Grupo Ferrer Internacional Business Overview
Table 243. Grupo Ferrer Internacional Ophthalmology Disorders Drug Product
Table 244. Grupo Ferrer Internacional Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 245. Grupo Ferrer Internacional Recent Development
Table 246. ID Pharma Company Details
Table 247. ID Pharma Business Overview
Table 248. ID Pharma Ophthalmology Disorders Drug Product
Table 249. ID Pharma Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 250. ID Pharma Recent Development
Table 251. InFlectis BioScience Company Details
Table 252. InFlectis BioScience Business Overview
Table 253. InFlectis BioScience Ophthalmology Disorders Drug Product
Table 254. InFlectis BioScience Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 255. InFlectis BioScience Recent Development
Table 256. Ionis Pharmaceuticals Company Details
Table 257. Ionis Pharmaceuticals Business Overview
Table 258. Ionis Pharmaceuticals Ophthalmology Disorders Drug Product
Table 259. Ionis Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2016-2021) & (US$ Million)
Table 260. Ionis Pharmaceuticals Recent Development
Table 261. Ixchel Pharma Company Details
Table 262. Khondrion Company Details
Table 263. Mimetogen Pharmaceuticals Company Details
Table 264. Mitotech Company Details
Table 265. M's Science Company Details
Table 266. Nanovector Company Details
Table 267. SanBio Company Details
Table 268. Research Programs/Design for This Report
Table 269. Key Data Information from Secondary Sources
Table 270. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Ophthalmology Disorders Drug Market Share by Type: 2020 VS 2027
Figure 2. Oral Features
Figure 3. Injection Features
Figure 4. External Use Features
Figure 5. Global Ophthalmology Disorders Drug Market Share by Application: 2020 VS 2027
Figure 6. Juvenile Macular Degeneration (Stargardt Disease) Case Studies
Figure 7. Leber Congenital Amaurosis (LCA) Case Studies
Figure 8. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Case Studies
Figure 9. Usher Syndrome Case Studies
Figure 10. Retinitis Pigmentosa (Retinitis) Case Studies
Figure 11. Ophthalmology Disorders Drug Report Years Considered
Figure 12. Global Ophthalmology Disorders Drug Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Ophthalmology Disorders Drug Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Ophthalmology Disorders Drug Market Share by Regions: 2020 VS 2027
Figure 15. Global Ophthalmology Disorders Drug Market Share by Regions (2022-2027)
Figure 16. Global Ophthalmology Disorders Drug Market Share by Players in 2020
Figure 17. Global Top Ophthalmology Disorders Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ophthalmology Disorders Drug as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Ophthalmology Disorders Drug Revenue in 2020
Figure 19. Global Ophthalmology Disorders Drug Revenue Market Share by Type (2016-2021)
Figure 20. Global Ophthalmology Disorders Drug Revenue Market Share by Type (2022-2027)
Figure 21. North America Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Ophthalmology Disorders Drug Market Share by Type (2016-2027)
Figure 23. North America Ophthalmology Disorders Drug Market Share by Application (2016-2027)
Figure 24. North America Ophthalmology Disorders Drug Market Share by Country (2016-2027)
Figure 25. United States Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Ophthalmology Disorders Drug Market Share by Type (2016-2027)
Figure 29. Europe Ophthalmology Disorders Drug Market Share by Application (2016-2027)
Figure 30. Europe Ophthalmology Disorders Drug Market Share by Country (2016-2027)
Figure 31. Germany Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Ophthalmology Disorders Drug Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Ophthalmology Disorders Drug Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Ophthalmology Disorders Drug Market Share by Region (2016-2027)
Figure 41. China Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Ophthalmology Disorders Drug Market Share by Type (2016-2027)
Figure 49. Latin America Ophthalmology Disorders Drug Market Share by Application (2016-2027)
Figure 50. Latin America Ophthalmology Disorders Drug Market Share by Country (2016-2027)
Figure 51. Mexico Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Ophthalmology Disorders Drug Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Ophthalmology Disorders Drug Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Ophthalmology Disorders Drug Market Share by Country (2016-2027)
Figure 57. Turkey Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Ophthalmology Disorders Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Sanofi Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 61. Bayer Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 62. Bausch + Lomb Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 63. Novartis Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 64. Usher Syndrome Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 65. Takeda Pharmaceutical Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 66. Roche Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 67. Pfizer Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 68. Allergan Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 69. Gilead Sciences Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 70. Kubota Pharmaceutical Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 71. Alkeus Pharmaceuticals Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 72. Astellas Pharma Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 73. Ferrer Corporate Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 74. Amgen Inc Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 75. Editas Medicine Inc Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 76. ProQR Therapeutics NV Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 77. ReNeuron Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 78. Amarantus BioScience Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 79. Ocugen Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 80. ReGenX Biosciences Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 81. Sucampo Pharmaceuticals Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 82. Orphagen Pharmaceuticals Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 83. Okuvision Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 84. Second Sight Medical Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 85. Acucela Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 86. Stealth BioTherapeutics Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 87. Sun Pharma Advanced Research Company Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 88. AmpliPhi Biosciences Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 89. Applied Genetic Technologies Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 90. Asklepios BioPharmaceutical Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 91. Biovista Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 92. Spark Therapeutics Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 93. Caladrius Biosciences Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 94. Dompe Farmaceutici Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 95. Dormant Projects Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 96. Grupo Ferrer Internacional Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 97. ID Pharma Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 98. InFlectis BioScience Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 99. Ionis Pharmaceuticals Revenue Growth Rate in Ophthalmology Disorders Drug Business (2016-2021)
Figure 100. Bottom-up and Top-down Approaches for This Report
Figure 101. Data Triangulation
Figure 102. Key Executives Interviewed
レーバー遺伝性視神経萎縮症薬のグローバル市場調査 2019年 The global Leber's Hereditary Optic Neuropathy Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Leber's Hereditary Optic Neuropathy Drug volume and value at global level, regional level and comp…- 世界のレーバー先天性黒内障（LCA）市場規模・現状・予測（2021年-2027年） Leber congenital amaurosis is a kind of autosomal recessive genetic disease, it is the main genetic disease that brings about children blindness, accompany mental nerve symptom, wait like intellectual inferior, hearing obstacle, epilepsy, conus cornea can happen when some age is older or spherical c…
- 視神経症薬のグローバル市場調査 2019年 The global Optic Neuropathy Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Optic Neuropathy Drug volume and value at global level, regional level and company level. From a global perspective, …
- 世界の黄斑変性症治療薬パイプライン市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Macular Degeneration Drug Pipeline Market The global Macular Degeneration Drug Pipeline market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high …
- 世界のリウマチ疾患治療薬市場規模・現状・予測（2021年-2027年） Treatment of drugs for regulating rheumatic diseases Rheumatic diseases are a series of diseases characterized by chronic pain. Some of the most common diseases are osteoarthritis (OA) and rheumatoid arthritis (RA), and most rheumatic diseases use basically universal pain control drugs. Treatment is…